Navigation Links
NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
Date:3/7/2009

EMERYVILLE, Calif., March 7 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective products for the treatment and prevention of a wide range of bacterial, fungal, and viral infections without developing resistance, today announced preclinical animal data showing that NVC-422, the Company's lead Aganocide(R) compound, was effective in treating subcutaneous dermatophyte (skin fungus) infections.

The study of NVC-422, which is a synthetic bioequivalent form of the most effective and rapidly-acting anti-infective molecules produced by white blood cells, revealed significant clinical and mycological efficacy compared to the untreated control group at all doses evaluated, with the highest clinical and mycological efficacy rates of 36.6% (p <0.0001) and 97.9% (p <0.05), respectively, achieved in the highest dose group. These data confirm previous preclinical results that showed a high level of activity for high dose NVC-422 against dermatophytes. The results were presented at the American Academy of Dermatology (AAD) 67th Annual Meeting in San Francisco (Abstract #2405).

"Dermatophytosis is a group of chronic and common skin infections that causes significant discomfort and cosmetic problems, and currently available drugs often do not provide adequate cure and cause unwanted side effects," said Mahmoud A. Ghannoum, Ph.D., Director of the Center for Medical Mycology, Department of Dermatology, University Hospitals of Cleveland, and Case Western Reserve University. "The significant clinical and mycological efficacy rates shown in this study demonstrate that topical NVC-422 penetrates the skin and hair at the infection site indicating that it has the potential to target and eliminate skin infections, including onychomycosis, tinea pedis, and tinea capitis. Importantly, these data provide strong s
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
3. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
4. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
5. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
6. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
9. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
10. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
11. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Mass. , Aug. 28, 2014  Decision ... system market will grow strongly through 2022 at ... percent. This will be largely supported by strong ... will increase demand for imaging procedures. The Indian ... allow more facilities to purchase or upgrade diagnostic ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Landscape Poland " an essential source of information ... market and provides insights into the demographic, regulatory, ... report provides valuable insights into the trends and ...
(Date:8/28/2014)... Japan , Aug. 28, 2014 ... of the post-marketing commitment and submissions of data ... including the United States ... Medicines Agency (EMA) and the Japanese Ministry of ... Pharmaceuticals and Medical Devices Agency (PMDA) for pioglitazone ...
Breaking Medicine Technology:Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 2Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6
... VIEW, Calif., Feb. 9, 2011 Concentric Medical, Inc. today ... ( T hrombectomy RE vascularization of large V ... in Portland, Oregon and at Capital Health in Trenton, New ... TREVO 2 and Capital Health was first to use the ...
... NEW YORK, Feb. 9, 2011 Reportlinker.com announces ... in its catalogue: Omega-3-acid ethyl ... http://www.reportlinker.com/p0366322/Omega-3-acid-ethyl-esters---Comprehensive-patent-search.html Eliminate unnecessary risk ... Pipeline Developer is a regularly updated, ...
Cached Medicine Technology:Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial 2Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial 3Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 2Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 3Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 4
(Date:8/29/2014)... For the fifth year in a row, ... observing September 26th as Mesothelioma Awareness Day, by attending ... , Members of the community who wish to ... will be providing t-shirts and signs to participating community ... have received attention from Al Roker and ...
(Date:8/29/2014)... Empty Nest Syndrome on Dr. Carol ... , Mothers and fathers, who dedicated the last ... laughing and sweating through parenting, launch their college ... Relief and parenting pride intermix with loss, depression ... Carol Francis as a Clinical Psychologist has helped ...
(Date:8/29/2014)... PreDiabetes Centers , the country’s leading prediabetes ... Web shoppers a 20% discount off orders of $100 or ... healthy living shop, beginning September 1. , Keeping your ... into the chilly fall season. , Autumn’s cooler, cozier weather ... usually ditch the healthy salads and opt for creamy soups, ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 TayganPoint Consulting ... that for the second time, Inc. Magazine has named ... in America. , Based on solid revenue growth of ... No. 2341 overall on the list. TayganPoint’s repeat ... environment of the past few years, is a demonstration ...
(Date:8/29/2014)... 2014 Innovations Television, produced by DMG Productions, ... of Innovations, focusing on health and elderly care, slated to ... number of Americans over 65 will nearly double by 2030, ... in 2030, for a total of 72 million people. Though ... have at least one chronic condition and use healthcare services ...
Breaking Medicine News(10 mins):Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Innovations with Ed Begley, Jr., Seeking Content for Upcoming Series on Health and Elder Care 2
... new asthma inhaler revealed that it has problems. This investigation was ... the funding for Ventolin inhalers in favour of Salamol. ... Only 15 of them were able to stick to the study. ... or due to the taste. Asthma stability had deteriorated in 93% ...
... According to researchers, a gene determines people’s sensitivity to ... chronic pain could be prevented by blocking the expression ... inflammation. This could be a breakthrough in development of ... about a quarter of them had the genetic variant ...
... be dangerous as the tablet’s special coating controls the release ... serious side effects. ,David Wright, who led a ... take drugs in patch, liquid or inhaler form.”,Difficulty in swallowing ... Studies have revealed that tablets are being crushed and given ...
... interesting study conducted at National University of Singapore recently ... November 1, 2006 edition, to study the tangible benefits ... discovered that a regular consumption of meals which are ... degenerative processes of the brain which is often indelibly ...
... Butler, a pioneering plastic and reconstructive surgeon has been ... ethics committee of the Royal Free Hospital, London to ... ,However the Royal College of Surgeons has called for ... transplantation. ,The surgery promises to transform the lives ...
... a new drug for treatment of obesity, has been found to ... with diabetes type 2. The research was done on 1,047 overweight ... and North America. ,Some of them were given 5 or ... a placebo, for a 1 year period. Those on the drug ...
Cached Medicine News:Health News:Gene determines pain threshold... 2Health News:Spices in curries spruce up aging minds 2Health News:Green Signal given to Full-Face Transplants 2Health News:Green Signal given to Full-Face Transplants 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: